Vimentin expression is retained in erythroid cells differentiated from human iPSC and ESC and indicates dysregulation in these cells early in differentiation.
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
29 04 2019
29 04 2019
Historique:
received:
31
01
2019
accepted:
04
04
2019
revised:
02
04
2019
entrez:
1
5
2019
pubmed:
1
5
2019
medline:
3
7
2020
Statut:
epublish
Résumé
Pluripotent stem cells are attractive progenitor cells for the generation of erythroid cells in vitro as have expansive proliferative potential. However, although embryonic (ESC) and induced pluripotent (iPSC) stem cells can be induced to undergo erythroid differentiation, the majority of cells fail to enucleate and the molecular basis of this defect is unknown. One protein that has been associated with the initial phase of erythroid cell enucleation is the intermediate filament vimentin, with loss of vimentin potentially required for the process to proceed. In this study, we used our established erythroid culture system along with western blot, PCR and interegation of comparative proteomic data sets to analyse the temporal expression profile of vimentin in erythroid cells differentiated from adult peripheral blood stem cells, iPSC and ESC throughout erythropoiesis. Confocal microscopy was also used to examine the intracellular localisation of vimentin. We show that expression of vimentin is turned off early during normal adult erythroid cell differentiation, with vimentin protein lost by the polychromatic erythroblast stage, just prior to enucleation. In contrast, in erythroid cells differentiated from iPSC and ESC, expression of vimentin persists, with high levels of both mRNA and protein even in orthochromatic erythroblasts. In the vimentin-positive iPSC orthochromatic erythroblasts, F-actin was localized around the cell periphery; however, in those rare cells captured undergoing enucleation, vimentin was absent and F-actin was re-localized to the enucleosome as found in normal adult orthrochromatic erythroblasts. As both embryonic and adult erythroid cells loose vimentin and enucleate, retention of vimentin by iPSC and ESC erythroid cells indicates an intrinsic defect. By analogy with avian erythrocytes which naturally retain vimentin and remain nucleated, retention in iPSC- and ESC-derived erythroid cells may impede enucleation. Our data also provide the first evidence that dysregulation of processes in these cells occurs from the early stages of differentiation, facilitating targeting of future studies.
Sections du résumé
BACKGROUND
Pluripotent stem cells are attractive progenitor cells for the generation of erythroid cells in vitro as have expansive proliferative potential. However, although embryonic (ESC) and induced pluripotent (iPSC) stem cells can be induced to undergo erythroid differentiation, the majority of cells fail to enucleate and the molecular basis of this defect is unknown. One protein that has been associated with the initial phase of erythroid cell enucleation is the intermediate filament vimentin, with loss of vimentin potentially required for the process to proceed.
METHODS
In this study, we used our established erythroid culture system along with western blot, PCR and interegation of comparative proteomic data sets to analyse the temporal expression profile of vimentin in erythroid cells differentiated from adult peripheral blood stem cells, iPSC and ESC throughout erythropoiesis. Confocal microscopy was also used to examine the intracellular localisation of vimentin.
RESULTS
We show that expression of vimentin is turned off early during normal adult erythroid cell differentiation, with vimentin protein lost by the polychromatic erythroblast stage, just prior to enucleation. In contrast, in erythroid cells differentiated from iPSC and ESC, expression of vimentin persists, with high levels of both mRNA and protein even in orthochromatic erythroblasts. In the vimentin-positive iPSC orthochromatic erythroblasts, F-actin was localized around the cell periphery; however, in those rare cells captured undergoing enucleation, vimentin was absent and F-actin was re-localized to the enucleosome as found in normal adult orthrochromatic erythroblasts.
CONCLUSION
As both embryonic and adult erythroid cells loose vimentin and enucleate, retention of vimentin by iPSC and ESC erythroid cells indicates an intrinsic defect. By analogy with avian erythrocytes which naturally retain vimentin and remain nucleated, retention in iPSC- and ESC-derived erythroid cells may impede enucleation. Our data also provide the first evidence that dysregulation of processes in these cells occurs from the early stages of differentiation, facilitating targeting of future studies.
Identifiants
pubmed: 31036072
doi: 10.1186/s13287-019-1231-z
pii: 10.1186/s13287-019-1231-z
pmc: PMC6489253
doi:
Substances chimiques
Vimentin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
130Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 102610
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 087430/Z/08
Pays : United Kingdom
Références
Blood. 2012 Jun 28;119(26):6296-306
pubmed: 22490681
Blood. 2008 Feb 15;111(4):2409-17
pubmed: 18032705
Cell. 1983 Dec;35(2 Pt 1):411-20
pubmed: 6317186
Exp Cell Res. 2010 Jul 1;316(11):1829-44
pubmed: 20171211
Proc Natl Acad Sci U S A. 1989 Jul;86(13):4882-6
pubmed: 2662187
Stem Cell Res. 2016 May 6;17(1):36-41
pubmed: 27558601
Exp Hematol. 2006 Dec;34(12):1635-42
pubmed: 17157159
Development. 1990 Sep;110(1):85-96
pubmed: 1706980
J Cell Biol. 1984 Jul;99(1 Pt 1):306-14
pubmed: 6376521
Eur Rev Med Pharmacol Sci. 2016 May;20(9):1733-9
pubmed: 27212164
Stem Cells Transl Med. 2016 Oct;5(10):1394-1405
pubmed: 27400796
Front Physiol. 2014 Jan 28;5:3
pubmed: 24478716
J Cell Sci. 1998 Jul;111 ( Pt 13):1897-907
pubmed: 9625752
J Biol Chem. 2006 Oct 13;281(41):30393-9
pubmed: 16901892
Haematologica. 2010 Dec;95(12):1985-8
pubmed: 21123437
Haematologica. 2010 Oct;95(10):1651-9
pubmed: 20494935
Nat Rev Mol Cell Biol. 2004 Aug;5(8):601-13
pubmed: 15366704
Cell. 1982 Aug;30(1):263-75
pubmed: 6751558
J Cell Mol Med. 2014 Apr;18(4):610-23
pubmed: 24447545
Stem Cells Int. 2011;2011:139851
pubmed: 22007239
Breast Cancer Res Treat. 2012 Aug;134(3):1081-93
pubmed: 22476851
EMBO J. 1983;2(9):1509-14
pubmed: 11892803
Stem Cells Dev. 2011 Sep;20(9):1639-47
pubmed: 21434814
Blood. 2017 Aug 31;130(9):1144-1155
pubmed: 28729432
Exp Cell Res. 2007 Jun 10;313(10):2050-62
pubmed: 17512929
J Cell Biol. 1996 Nov;135(4):991-1007
pubmed: 8922382
Cell Rep. 2016 Aug 2;16(5):1470-1484
pubmed: 27452463
Cell Mol Biol (Noisy-le-grand). 1997 Sep;43(6):851-60
pubmed: 9359632
Blood. 2010 Oct 28;116(17):3321-30
pubmed: 20628147
Nat Commun. 2017 Mar 14;8:14750
pubmed: 28290447
Mol Cell Biol. 1987 Nov;7(11):3955-70
pubmed: 3481037
PLoS One. 2014 Jul 14;9(7):e100874
pubmed: 25019302
Stem Cells. 2015 Aug;33(8):2431-41
pubmed: 25850942
Blood. 2011 Apr 14;117(15):4008-11
pubmed: 21343609
Curr Opin Hematol. 2012 May;19(3):163-9
pubmed: 22406823
Haematologica. 2015 Jan;100(1):32-41
pubmed: 25326431
Blood. 2013 Apr 18;121(16):3246-53
pubmed: 23422750
Mol Cell Proteomics. 2016 Jun;15(6):1938-46
pubmed: 27006477
Blood. 2005 Sep 15;106(6):2200-5
pubmed: 15933051
J Cell Sci. 2009 Jul 15;122(Pt 14):2554-66
pubmed: 19549685
PLoS One. 2013;8(4):e60300
pubmed: 23565219